RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Yaoyanshe, a Shanghai on-line AI-based CRO/CMO, raised $42 million in a C funding round led by Eastern Bell Capital and Sequoia China. Founded in 2015, Yaoyanshe offers Trial.Link, a repository of China clinical trial information that connects biopharmas, hospitals, researchers, industry practitioners and patients. The company says the platform currently includes more than 180 hospitals and 300 drug manufacturers. Yaoyanshe believes the platform shortens the timeline for clinical development by 20% and lowers development costs by 15%. In addition, the company is building a similar platform to cover China’s drug R&D landscape. Source: China Biotoday
